Healthy Skepticism Library item: 10753

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Dyer C.
NICE's decision on dementia drugs was 'irrational', High Court is told
BMJ 2007 Jun 30; 334:(7608):1337
http://www.bmj.com/cgi/content/full/334/7608/1337-a

Full text:

The regulatory body that decides which treatments the NHS should pay for was accused of “irrational” decision making in the High Court this week for denying drugs to patients in the mild stage of Alzheimer’s disease.

The National Institute for Health and Clinical Excellence (NICE), which issues its guidance on the basis of cost benefit analyses, is facing its first legal challenge to a decision to restrict a drug’s availability on the NHS.

The unprecedented case was brought to the High Court in London this week by two drug companies and by the Alzheimer’s Society, representing patients and carers.

NICE’s guidance last year meant that nearly 100 000 patients a year in England, Wales, and Northern Ireland with mild Alzheimer’s disease were no longer entitled to certain drugs on the NHS. The drugs are the acetyl cholinesterase inhibitors donepezil (Aricept), rivastigmine (Exelon), and galantamine (Reminyl). Eisai, the Japanese manufacturer of . . .